Published in Clin Exp Metastasis on August 01, 2015
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 4.04
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol (2011) 3.33
New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell (2006) 3.11
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol (1998) 3.05
Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer (2010) 2.94
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 2.93
Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One (2007) 2.77
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J Biol Chem (2006) 2.17
PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res (2003) 1.94
Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J (2004) 1.94
Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol (2011) 1.87
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A (2006) 1.85
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res (2006) 1.79
Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol (2007) 1.76
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol (2004) 1.74
From Tpr-Met to Met, tumorigenesis and tubes. Oncogene (2007) 1.69
Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J (1992) 1.68
Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol (2011) 1.56
Principles of liver regeneration and growth homeostasis. Compr Physiol (2013) 1.52
Identification of a competitive HGF antagonist encoded by an alternative transcript. Science (1991) 1.44
Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res (2010) 1.41
Activation of Rap1 promotes prostate cancer metastasis. Cancer Res (2009) 1.41
Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene (1999) 1.38
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (2008) 1.33
The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene (2012) 1.30
Knockdown of ASIC1 and epithelial sodium channel subunits inhibits glioblastoma whole cell current and cell migration. J Biol Chem (2009) 1.28
Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab (2013) 1.26
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene (2005) 1.25
Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res (2010) 1.21
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer (2007) 1.21
Extracellular matrix components in breast cancer progression and metastasis. Breast (2013) 1.21
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling. J Biol Chem (2004) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
A Trio-Rac1-Pak1 signalling axis drives invadopodia disassembly. Nat Cell Biol (2014) 1.15
Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci (2008) 1.14
Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol (1999) 1.14
CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res (2008) 1.14
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J Biol Chem (1996) 1.13
PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol (2009) 1.12
Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res (2014) 1.11
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. J Biol Chem (2001) 1.10
Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol (2012) 1.06
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate (2010) 1.06
CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Carcinogenesis (2012) 1.06
CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta (2013) 1.05
The deubiquitinating enzyme USP8 promotes trafficking and degradation of the chemokine receptor 4 at the sorting endosome. J Biol Chem (2010) 1.04
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene (2014) 1.04
Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene (1999) 1.04
The transcription factor SPDEF suppresses prostate tumor metastasis. J Biol Chem (2012) 1.03
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther (2005) 1.03
Functional evidence implicating S100P in prostate cancer progression. Int J Cancer (2008) 1.03
Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J Surg Res (2009) 1.03
Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci (2013) 1.02
Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer (2009) 1.02
Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure (1998) 1.01
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett (2011) 1.01
The roles of CD73 in cancer. Biomed Res Int (2014) 1.01
P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res (2005) 1.00
Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. Cancer Metastasis Rev (2012) 0.99
Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis (2012) 0.99
Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J Biol Chem (2009) 0.99
Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ (1998) 0.98
The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol (2012) 0.98
Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol Cell Biol (2000) 0.98
Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem (2012) 0.97
TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer (2010) 0.97
Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget (2014) 0.96
CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis (2012) 0.96
Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J (1997) 0.96
U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int (2005) 0.96
Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci U S A (2007) 0.95
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated Snail phosphorylation. Carcinogenesis (2009) 0.94
Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol (2013) 0.93
RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (2014) 0.93
Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol (2005) 0.93
Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene (2012) 0.92
Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene (2012) 0.92
Overexpression of Rap-1A indicates a poor prognosis for oral cavity squamous cell carcinoma and promotes tumor cell invasion via Aurora-A modulation. Am J Pathol (2012) 0.92
The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost (2013) 0.91
E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci (2003) 0.91
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell (2014) 0.90
Actin binding proteins: their ups and downs in metastatic life. Cell Adh Migr (2013) 0.90
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer (2011) 0.90
Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res (2010) 0.90
Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. PLoS One (2016) 0.76